公开(公告)号：US20200246338A1

公开(公告)日：2020-08-06

申请号：US16722384

申请日：2019-12-20

Applicant: Array BioPharma Inc.

Inventor： Giordano Caponigro ,  Darrin Stuart ,  Laure De Parseval

IPC: A61K31/506 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  C12Q1/6886

Abstract: Reversing resistance to a B-Raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3, EGFR, MAP2K1, MAP2K2, NRAS, KRAS, HRAS, PTEN, PIK3CA, and P16 and administering a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance to the B-Raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.

公开(公告)号：US20200230108A1

公开(公告)日：2020-07-23

申请号：US16580505

申请日：2019-09-24

Applicant: Array BioPharma Inc.

Inventor： Giordano Caponigro ,  Zhu Alexander Cao

IPC: A61K31/4184 ,  A61K31/506 ,  A61K39/395 ,  A61P35/04 ,  A61K45/06 ,  A61K31/573 ,  A61P35/00 ,  C07K16/28 ,  A61K9/00

Abstract: Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.

公开(公告)号：US10548894B2

公开(公告)日：2020-02-04

申请号：US15875031

申请日：2018-01-19

Applicant: Array BioPharma Inc.

Inventor： Giordano Caponigro ,  Darrin Stuart ,  Laure De Parseval

IPC: A61K31/506 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  C12Q1/6886

Abstract: Reversing resistance to a B-Raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3 EGFR, MAP2K1, MAP2K2, NRAS, KRAS HRAS, PTEN, PIK3CA, and P16 and administering a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance to the B-Raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.

公开(公告)号：US20190105303A1

公开(公告)日：2019-04-11

申请号：US16208172

申请日：2018-12-03

Applicant: Array BioPharma Inc.

Inventor： Giordano Caponigro ,  Zhu Alexander Cao

IPC: A61K31/4184 ,  A61K9/00 ,  A61P35/04

Abstract: Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.

公开(公告)号：US20230044943A1

公开(公告)日：2023-02-09

申请号：US17745136

申请日：2022-05-16

Applicant: ARRAY BIOPHARMA INC.

Inventor： Giordano Caponigro ,  Zhu Alexander Cao

IPC: A61K31/4184 ,  A61K31/506 ,  A61K39/395 ,  A61P35/04 ,  A61K45/06 ,  A61K31/573 ,  A61P35/00 ,  C07K16/28 ,  A61K9/00

Abstract: Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.

公开(公告)号：US11376239B2

公开(公告)日：2022-07-05

申请号：US16580505

申请日：2019-09-24

Applicant: Array BioPharma Inc.

Inventor： Giordano Caponigro ,  Zhu Alexander Cao

IPC: A61K31/4184 ,  A61K31/506 ,  A61K39/395 ,  A61P35/04 ,  A61K45/06 ,  A61K31/573 ,  A61P35/00 ,  C07K16/28 ,  A61K9/00 ,  A61K39/00

Abstract: Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.